Menu Menu


/ News
Saturday, 1st October 2022 | 8,342 veterinary jobs online | 82 people actively seeking work | 5,232 practices registered

Veterinary Industry News

Send us your news

Stonehaven Incubate Launches New Company Aiming To Tackle Canine Osteoarthritis

1 year ago

11th May, 2021 11h56

Stonehaven Incubate

Stonehaven Incubate has partnered with human health player Regenosine to launch Vetosine, a new company that will develop and commercialize a first-in-class disease modifying osteoarthritis drug (DMOAD) for animals, with an initial focus on dogs.

“Vetosine’s proprietary adenosine-based treatment will be a real game changer for the industry,” said Charlie Dawson, Venture Partner at Stonehaven Incubate. “At the moment, veterinarians and pet owners have few therapy options for dogs with osteoarthritis beyond simple nonsteroidal anti-inflammatory drugs (NSAIDs), diet and exercise. Vetosine will provide a proven disease modifying drug that will strengthen clinical outcomes and improve the pet’s quality of life.”

Dr. Bruce Cronstein, co-founder of Regenosine, was first to elucidate the role of adenosine in maintaining healthy joint cartilage.

“We have now developed proprietary formulations for adenosine replacement which have demonstrated disease modifying outcomes in gold standard preclinical models for osteoarthritis,” said Dr. Siddhesh Angle, co-founder and CEO of Regenosine. “While we endeavour to make this first-in-class therapy a success for human medicine, we are very excited to partner with Stonehaven Incubate to expand its horizon into the animal health space.”

Vetosine will have an exclusive global license to develop the new technology in animal health while Regenosine will continue to focus on developing the same technology for the human health market.

“Vetosine is perfectly aligned with Stonehaven Incubate’s mission to transform animal health by leveraging disruptive human health technologies,” said Jarne Elleholm, CEO of Stonehaven Incubate. “We are excited to add another company to our portolio as we continue to explore other opportunities to translate breakthrough human health technologies into the animal health space.”

More from Stonehaven Incubate